Nearly half of the 70,000 GLP-1 drug users surveyed reported at least one side effect. This reveals a significant trade-off for those seeking weight loss with medications like Eli Lilly's obesity drug, which are gaining traction. Nausea alone affects up to 50% of patients, according to PMC.
GLP-1 drugs are highly effective for weight loss, but a large percentage of users experience diverse side effects that can derail treatment. Patients must weigh these benefits against potential discomfort.
Given the widespread reporting of varied side effects, robust patient education and expectation management regarding adverse reactions will likely become crucial for successful GLP-1 drug adoption and adherence.
Beyond the Gut: A Spectrum of Side Effects
While GLP-1 medications are often linked to digestive issues like nausea, their impact reaches further. Approximately 17 percent of users reported fatigue, according to Everydayhealth, suggesting a broader systemic effect. More surprisingly, about 4 percent of users noted menstrual changes, indicating these drugs might influence hormonal regulation across different patient demographics.
Understanding Less Common, But Notable Reactions
Beyond common issues, patients report less frequent but notable reactions. Temperature-related complaints—chills, feeling cold, and hot flashes—were each reported by 1 to 4 percent of users, according to Everydayhealth. These experiences, though less common, significantly impact daily comfort and underscore the drug's broad systemic reach.
Side Effects and Treatment Adherence
For long-term treatment, understanding which side effects lead to discontinuation is key. Many common adverse effects, like injection site reactions, headaches, and nasopharyngitis, are frequently reported but generally manageable, according to PMC. Patients often tolerate these issues. The real challenge lies in distinguishing between manageable reactions and those that truly diminish quality of life, leading to non-adherence.
Common Questions on Side Effect Rates
Are there any FDA warnings for Eli Lilly's weight loss medication?
While the FDA warns of known risks for all medications, a significant gap in patient education exists for GLP-1 side effects. Real-world data from Everydayhealth shows 44% of users experience at least one side effect, compared to 24% in an Orforglipron trial, according to CNBC. This disparity suggests patients may be unprepared for the actual experience, potentially leading to disappointment and non-adherence.
What is the latest news on Eli Lilly's obesity drug in 2026?
By 2026, discussions around Eli Lilly's obesity drugs often highlight systemic side effects beyond gastrointestinal issues, including fatigue (17%) and menstrual changes (4%) among the 44% of users reporting complaints, per Everydayhealth. Companies marketing these drugs appear to be downplaying this broader spectrum, risking patient backlash from those unprepared for the full reality of treatment.
As of Q3 2026, Eli Lilly and other pharmaceutical companies will likely face increasing scrutiny regarding patient education, as the success of obesity drugs appears to hinge on preparing patients for the diverse side effects they may encounter.
